Decatur Capital Management Inc. trimmed its holdings in Clorox Co (NYSE:CLX) by 2.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,777 shares of the company’s stock after selling 750 shares during the period. Decatur Capital Management Inc.’s holdings in Clorox were worth $5,018,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Mn Services Vermogensbeheer B.V. grew its stake in Clorox by 0.6% in the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 70,968 shares of the company’s stock valued at $11,388,000 after buying an additional 400 shares in the last quarter. Deutsche Bank AG grew its stake in Clorox by 10.2% in the 4th quarter. Deutsche Bank AG now owns 307,703 shares of the company’s stock valued at $47,425,000 after buying an additional 28,361 shares in the last quarter. SlateStone Wealth LLC grew its stake in Clorox by 13.6% in the 1st quarter. SlateStone Wealth LLC now owns 5,043 shares of the company’s stock valued at $809,000 after buying an additional 605 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its stake in Clorox by 1.1% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 35,017 shares of the company’s stock valued at $5,619,000 after buying an additional 384 shares in the last quarter. Finally, Sadoff Investment Management LLC grew its stake in Clorox by 0.7% in the 1st quarter. Sadoff Investment Management LLC now owns 127,494 shares of the company’s stock valued at $20,458,000 after buying an additional 945 shares in the last quarter. Institutional investors and hedge funds own 76.92% of the company’s stock.
In other news, SVP Denise Garner sold 20,399 shares of Clorox stock in a transaction on Friday, June 7th. The shares were sold at an average price of $157.61, for a total transaction of $3,215,086.39. Following the completion of the sale, the senior vice president now directly owns 4,896 shares of the company’s stock, valued at approximately $771,658.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.40% of the company’s stock.
Clorox (NYSE:CLX) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.88 EPS for the quarter, beating analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.69 billion. Clorox had a net margin of 13.20% and a return on equity of 118.88%. The business’s revenue for the quarter was down 3.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.66 EPS. Equities analysts anticipate that Clorox Co will post 6.4 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 16th. Stockholders of record on Wednesday, July 31st will be issued a dividend of $1.06 per share. This is an increase from Clorox’s previous quarterly dividend of $0.96. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date of this dividend is Tuesday, July 30th. Clorox’s payout ratio is currently 67.09%.
A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Clorox from a “sell” rating to a “hold” rating and set a $175.00 price objective for the company in a research note on Monday, July 29th. BMO Capital Markets set a $168.00 price target on shares of Clorox and gave the company a “buy” rating in a research report on Thursday, May 2nd. Bank of America restated a “neutral” rating and set a $154.00 price target (down from $165.00) on shares of Clorox in a research report on Thursday, May 2nd. Citigroup set a $156.00 price target on shares of Clorox and gave the company a “hold” rating in a research report on Thursday, May 23rd. Finally, Morgan Stanley boosted their price target on shares of Clorox from $141.00 to $144.00 and gave the company an “underweight” rating in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $154.07.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Further Reading: What are municipal bonds?
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.